Charles Schwab Investment Management Inc. Decreases Holdings in Guardant Health, Inc. $GH

Charles Schwab Investment Management Inc. lowered its holdings in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 2.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 996,506 shares of the company's stock after selling 20,027 shares during the period. Charles Schwab Investment Management Inc. owned about 0.80% of Guardant Health worth $42,451,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the business. IQ EQ FUND MANAGEMENT IRELAND Ltd bought a new position in Guardant Health in the first quarter valued at $384,000. PNC Financial Services Group Inc. grew its position in Guardant Health by 25.6% in the first quarter. PNC Financial Services Group Inc. now owns 2,638 shares of the company's stock valued at $112,000 after purchasing an additional 537 shares in the last quarter. US Bancorp DE grew its position in Guardant Health by 11.8% in the first quarter. US Bancorp DE now owns 36,698 shares of the company's stock valued at $1,563,000 after purchasing an additional 3,876 shares in the last quarter. Private Advisory Group LLC bought a new position in Guardant Health in the first quarter valued at $475,000. Finally, Natixis Advisors LLC bought a new position in Guardant Health in the first quarter valued at $984,000. Institutional investors own 92.60% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on GH shares. Barclays lifted their price objective on shares of Guardant Health from $55.00 to $60.00 and gave the company an "overweight" rating in a research report on Thursday, May 1st. Scotiabank lifted their price objective on shares of Guardant Health from $57.00 to $60.00 and gave the company a "sector outperform" rating in a research report on Thursday, July 31st. Stifel Nicolaus lifted their price objective on shares of Guardant Health from $53.00 to $60.00 and gave the company a "buy" rating in a research report on Thursday, May 1st. Raymond James Financial lifted their price objective on shares of Guardant Health from $59.00 to $61.00 and gave the company an "outperform" rating in a research report on Thursday, July 31st. Finally, UBS Group lifted their target price on shares of Guardant Health from $65.00 to $70.00 and gave the stock a "buy" rating in a report on Thursday, May 1st. One analyst has rated the stock with a Strong Buy rating and sixteen have given a Buy rating to the stock. According to data from MarketBeat, Guardant Health presently has an average rating of "Buy" and an average target price of $57.50.

Guardant Health Stock Up 1.4%

GH traded up $0.85 during trading on Friday, hitting $62.13. 717,091 shares of the company traded hands, compared to its average volume of 2,387,563. The firm has a market cap of $7.75 billion, a P/E ratio of -18.68 and a beta of 1.43. The stock's fifty day moving average is $50.02 and its 200 day moving average is $45.87. Guardant Health, Inc. has a one year low of $20.14 and a one year high of $62.81.

Guardant Health (NASDAQ:GH - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.08. The company had revenue of $232.09 million for the quarter, compared to the consensus estimate of $211.19 million. Guardant Health's quarterly revenue was up 31.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.84) EPS. Guardant Health has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Insider Activity at Guardant Health

In other Guardant Health news, Director Musa Tariq sold 3,213 shares of the stock in a transaction dated Wednesday, June 18th. The shares were sold at an average price of $49.47, for a total transaction of $158,947.11. Following the completion of the transaction, the director owned 7,190 shares in the company, valued at $355,689.30. This trade represents a 30.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Meghan V. Joyce sold 3,337 shares of the stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $47.22, for a total transaction of $157,573.14. Following the transaction, the director owned 11,150 shares of the company's stock, valued at $526,503. This represents a 23.03% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 235,542 shares of company stock valued at $11,852,491 in the last 90 days. 6.10% of the stock is currently owned by company insiders.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.